Dr Lal Pathlabs Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹31.8K Cr
The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance. The company delivered a strong Q1 FY27 performance with Profit After Tax (PAT) growing 27.2% to Rs.
From Dr Lal Pathlabs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹1,895
Market Cap
₹31.8K Cr
P/E Ratio
56.5
Revenue Rank
Margin Rank
How does Dr Lal Pathlabs rank in Healthcare Services?
Compare Dr Lal Pathlabs against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Dr Lal Pathlabs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance.
- →Patient volume growth guidance is around 6%-7%, with Q1 patient volume growth ahead at 8%, but the company awaits more data post Q2 for better clarity.
- →Swasthfit segment is expected to sustain high teens growth (~20%), expanding acceptance in Tier 2 and Tier 3 geographies.
- →Growth is broad-based across geographies, including Delhi NCR, West India (especially Suburban), and rural outreach programs in 7 states.
- →The company plans to add 12-15 new labs and 3-4 high-end radiology centers during the year to support growth.
- →The expectation is that realization improvements will continue in the coming quarters supported by favorable test and geography mix, though price increases are only expected later in the year if needed.
📈 Profitability & Margins
Rank 3- →The company delivered a strong Q1 FY27 performance with Profit After Tax (PAT) growing 27.2% to Rs. 170 crore and EPS rising 27.8% to Rs. 10.1.
- →Management remains confident in sustainable and profitable growth supported by structural volume tailwinds, expanding diagnostic footprint, and focus on specialized tests.
- →There is an expectation of maintaining targeted sustainable revenue growth over the medium term, driven by volume growth, pricing levers, and geography/test mix improvements.
- →EBITDA margin for Q1 was strong at 31%, with previous guidance maintained at 27%-28%, though reinvestment into growth remains a priority.
- →The company anticipates reinvesting margin benefits into the business to support future expansion, with clearer guidance to be given post H1 FY27.
- →Price increases are considered a strategic lever and may be implemented towards the end of the fiscal year depending on cost pressures and competition.
- →International expansion efforts targeting Africa, Middle East, CIS, and Southeast Asia are planned over a 3-5 year horizon, indicating long-term growth potential.
🏗️ Capital Expenditure Plans
Yes- →Majority of cash utilization will be on mergers and acquisitions (M&As), especially to expand presence in underpenetrated regions like West and South India.
- →Capex for the current and next year is expected to be around Rs. 140-150 crore.
- →Investments are also planned for rolling out high-end radiology centers, particularly in Delhi NCR and Tier 2 markets in North India, with plans for 3-4 new radiology centers this year.
- →Focus on inorganic growth in international markets like Africa, Middle East (GCC), CIS, and Southeast Asia as a longer-term plan (3-5 years horizon).
- →Investment in healthcare innovation via acquisition of 30% stake in Neuome Technologies Private Limited (sample preservation and biobanking solutions).
- →Network expansion planned with addition of 12-15 new diagnostic labs this year, similar to last year.
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or future plans for fundraising through debt or equity.
- →The company currently holds a strong cash position with approximately Rs. 1,700 crore in cash and equivalents.
- →Management indicated that the primary use of cash will be for mergers and acquisitions (M&As) and capex, particularly for rolling out high-end radiology centers.
- →There is no indication or guidance regarding new debt or equity issuance in the discussions or Q&A.
- →The company appears focused on utilizing internal cash resources for growth rather than raising new capital at this stage.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Dr Lal Pathlabs Q1 FY27 results?
The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance. The company delivered a strong Q1 FY27 performance with Profit After Tax (PAT) growing 27.2% to Rs.
What is Dr Lal Pathlabs share price analysis?
Dr Lal Pathlabs currently shows a below-average growth signal. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs planning capital expenditure?
Majority of cash utilization will be on mergers and acquisitions (M&As), especially to expand presence in underpenetrated regions like West and South India. - Capex for the current and next year is expected to be around Rs.
Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.